Japanese Life Sciences Stock News

Mitsubishi HC Capital recently reported record net income and asset growth for FY2025, with Aviation and Logistics emerging as key profit engines, supported by expanded asset holdings and subsidiary fiscal period changes. This breadth of earnings growth underpins management’s emphasis on maintaining stable earnings and dividends into FY2026, highlighting the company’s diversified profit base. With FY2025 record results led by Aviation and Logistics, we’ll explore what this means for...

NEC (TSE:6701) is back in focus after the launch of Cloud Calling for UNIVERGE BLUE with KDDI and Intermedia, a nationwide cloud voice service targeting customers who are shifting away from legacy PBX systems. See our latest analysis for NEC. Despite recent headlines around Cloud Calling and NEC's AI recognition at the Newsweek AI Impact Awards, momentum in the share price has been mixed, with a 3.7% 7 day share price return alongside a year to date share price decline of 21.7%. The 5 year...

Nippon Express Holdings recently outlined plans for large-scale land sales and broader asset recycling to optimize its balance sheet, unlock hidden asset value and support progress toward its JPY 100 billion operating profit goal. By shifting underused real estate into financial capacity and aiming to raise return on equity, the company is trying to reshape how efficiently it converts its substantial asset base into shareholder value. We’ll now examine how Nippon Express Holdings’ asset...

AM Best recently affirmed the A+ (Superior) Financial Strength Ratings and "aa" (Superior) Long-Term Issuer Credit Ratings for Mitsui Sumitomo Insurance, Aioi Nissay Dowa Insurance, and assigned the same high ratings to MSIG Specialty Insurance America, all with stable outlooks. This affirmation and new assignment highlight the central role of these core and US operations in underpinning MS&AD Insurance Group Holdings’ overall resilience. Next, we’ll examine how AM Best’s reaffirmed A+...

Medium term plan BSP2030 comes into focus JGC Holdings (TSE:1963) has scheduled a special call to outline its medium term management plan, BSP2030, giving investors fresh detail on how the engineering and functional materials group aims to position its business. See our latest analysis for JGC Holdings. JGC Holdings' share price has climbed 32.8% year to date, alongside a 19.7% 90 day share price return and a 1 year total shareholder return of 118.9%. This suggests stronger momentum as...

IHI Corporation recently disclosed that subsidiary IHI Aerospace was suspended from competitive bidding on Japan Aerospace Exploration Agency contracts after improper cost claims and prematurely reported work, prompting internal reviews of the impact on its order pipeline. Beyond the immediate compliance issue, the episode raises fresh questions about execution risk in IHI’s aero and defense ambitions outlined at its recent Investor Day. We’ll now examine how the bidding suspension at IHI...

Stock performance snapshot Nissan Motor (TSE:7201) has been under pressure recently, with the stock down 1.6% on the day, 12.3% over the past week, and 9.9% over the past 3 months. Over the past year the stock is down 3.3%, with year to date performance down 11.4%. Longer term holders have seen declines of 31.6% over 3 years and 32.5% over 5 years. See our latest analysis for Nissan Motor. The recent 12.3% decline in the 7 day share price return and 9.9% decline over 3 months suggest momentum...

Why Kansai Electric Power Company (TSE:9503) is on investor watchlists today Kansai Electric Power Company (TSE:9503) stock has attracted attention after a mixed set of performance signals, with the share price down over the past month but showing a strong 1 year total return. See our latest analysis for Kansai Electric Power Company. At a share price of ¥2,341, Kansai Electric Power Company has seen its 1 month share price return fall 4.1% and its year to date share price return soften...

Olympus stock overview after recent performance Olympus (TSE:7733) has drawn fresh attention after a strong run over the past month, with the stock up about 20% and roughly 35% over the past 3 months, prompting closer scrutiny of its medical equipment business. See our latest analysis for Olympus. The recent 20.1% 1 month share price return and 35.5% 3 month share price return contrast with a weaker year to date share price return and a 1 year total shareholder return that is slightly...

Funding event reframes Astroscale Holdings (TSE:186A) for investors Astroscale Holdings (TSE:186A) has completed multi billion yen equity and convertible bond financing with Hulic and SKY Perfect JSAT. This funding event reshapes its balance sheet and future spending capacity in space services. See our latest analysis for Astroscale Holdings. That funding news has arrived after a sharp run up in the stock, with a 90 day share price return of 107.75% and a 1 year total shareholder return of...

Record FY2025 earnings put Mitsubishi HC Capital (TSE:8593) in focus Mitsubishi HC Capital (TSE:8593) recently reported record FY2025 net income and asset growth, with Aviation and Logistics playing key roles. Higher interim dividends and broader earnings strength have put the stock firmly on investor watchlists. See our latest analysis for Mitsubishi HC Capital. Despite record FY2025 earnings, the stock has recently cooled, with the 30 day share price return down 9.91% and the 90 day share...

In late May 2026, Daiichi Sankyo announced it would present more than 25 oncology abstracts at the ASCO 2026 meeting, showcasing phase 3 data for Enhertu and Datroway across multiple tumor types alongside earlier-stage DXd antibody-drug conjugate programs. These data underpin several recent approvals and label expansions for Enhertu and Datroway, underscoring how Daiichi Sankyo is turning its in-house ADC platform and global partnerships into an increasingly broad commercial oncology...

Why the Hitachi collaboration with Intel matters for shareholders Hitachi (TSE:6501) has drawn fresh attention after announcing a collaboration with Intel to develop physical AI, advanced computing, and digital infrastructure across manufacturing, energy, mobility, and other industrial sectors. The partnership targets five areas: foundry tools, quantum computing, energy optimization, custom silicon and edge AI, and factory automation. It aims to pair Hitachi's IT and operational expertise...

Square Enix announced FINAL FANTASY VII REVELATION, the third and final entry in the FINAL FANTASY VII Remake Series, scheduled for a simultaneous multi-platform release in Spring 2027 on PlayStation 5, Nintendo Switch 2, Xbox Series X|S and PC, while FINAL FANTASY VII REBIRTH has recently expanded to these platforms as well. This culmination of the remake project, with unified releases across all major modern platforms and new gameplay features, underscores Square Enix’s focus on deepening...

Aozora Bank, Ltd. announced a Quarterly dividend of ¥23.0000 per share, payable on September 2, 2026, with an ex-date of June 29, 2026 and a record date of June 30, 2026. This dividend declaration highlights how Aozora Bank is defining its current approach to shareholder returns through scheduled cash distributions. We will now examine how this clarified ¥23 per-share dividend policy shapes Aozora Bank’s investment narrative for current and prospective investors. The future of work is here...

Last week, you might have seen that Sekisui House, Ltd. ( TSE:1928 ) released its first-quarter result to the market...

AI is no longer just a big tech story. With credit demand still holding up, global bond markets reacting to interest rate expectations, and employment data pointing to ongoing economic activity, investors are looking for focused ways to gain exposure to AI without relying only on giants. The AI Small Caps screener targets smaller companies working in areas like machine learning, automation, and data intelligence, where early-stage progress can meaningfully change the long term story. In this...

If you are wondering whether ORIX at ¥6,113 still offers value after a strong run, this article walks through what the current price might be implying. The stock has been volatile in recent periods, with a decline of 2.0% over the last week, a 16.4% gain over the last 30 days, a 32.4% gain year to date, and a 107.1% gain over the last year, while the 3 year and 5 year returns are very large. Recent coverage has highlighted ORIX in the context of broader interest in Japanese financial stocks,...

With inflation, interest rates and bond yields all pulling investors in different directions, it can feel hard to know where to look next. One area that often gets less attention is smaller high quality companies that are not yet crowded with big institutional money. That is exactly what the High-Quality Undiscovered Gems screener aims to highlight. It focuses on strong fundamentals in a world of mixed growth signals and patchy sentiment. In this article, you will see 3 stocks from this...

Hi-Lex (TSE:7279) opened its Q2 2026 scorecard with revenue of ¥103.5b and basic EPS of ¥40.63, alongside trailing twelve month EPS of ¥1,116.54 that is heavily influenced by a ¥40.0b one off gain and a trailing net margin of 11.5% compared with 1.2% a year earlier. The company has seen revenue move from ¥74.8b in Q2 2025 to ¥103.5b in Q2 2026 and quarterly basic EPS shift from ¥27.40 to ¥40.63 over the same period. Trailing twelve month EPS has risen from ¥59.44 in Q1 2025 to ¥1,116.54 in Q2...

Software Service (TSE:3733) has put up another solid quarter, with Q2 2026 revenue at ¥14.9 billion and basic EPS of ¥364.38, backed by trailing 12 month EPS of ¥1,131.23 and net income of ¥5.9 billion on revenue of ¥46.5 billion. Over the last six reported quarters, revenue has ranged from ¥8.6 billion to ¥14.9 billion while quarterly basic EPS has moved between ¥170.77 and ¥382.30, giving you a clear view of how the earnings power has tracked the top line. With a trailing net profit margin...

Setting the scene for Sumitomo Pharma’s recent share performance Sumitomo Pharma (TSE:4506) has seen its share price move in different directions across timeframes, with a gain of 1.6% over the past day and a decline of 25.2% over the past 3 months. See our latest analysis for Sumitomo Pharma. At a share price of ¥1,437.0, the stock has recently fallen over shorter periods, with the 30 day share price return down 16.9% and the year to date share price return down 41.6%. However, the 1 year...

In late May 2026, Sumitomo Mitsui Banking Corporation and Toshiba Corporation launched two quantum-driven diversified equity indices for Japanese and U.S. stocks, while Sumitomo Mitsui Financial Group reported ongoing progress in its large-scale share repurchase program authorized through July 2026. This combination of advanced quantum optimization for portfolio construction and active capital management highlights Sumitomo Mitsui’s push to integrate cutting-edge technology with balance...

Marui Group (TSE:8252) reported fourth quarter fiscal 2026 results that surpassed earnings expectations, with record operating profit in its FinTech segment supported by higher merchant commission rates and continued SUKI-centric and digital transformation initiatives. See our latest analysis for Marui Group. At a share price of ¥2,734.5, the stock has seen its 1 day share price return rise 1.77%, but its 30 day return is down 8.56% and the year to date share price return is down 15.08%. The...